Seattle Genetics to Present at Upcoming Investor Conferences

BOTHELL, Wash.–(BUSINESS WIRE)– Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management
will present at the following upcoming investor conferences. The
presentations will be webcast live and available for replay from the
Seattle Genetics website at www.seattlegenetics.com
in the Investors
and News section.

Bank of America Merrill Lynch 2016 Health Care Conference
Wednesday,
May 11, 11:20 a.m. Pacific Time, Las Vegas

UBS Global Healthcare Conference
Tuesday, May 24, 10:30 a.m.
Eastern Time, New York

About Seattle Genetics

Seattle Genetics is an innovative biotechnology company that develops
and commercializes novel antibody-based therapies for the treatment of
cancer. The company’s industry-leading antibody-drug conjugate (ADC)
technology harnesses the targeting ability of antibodies to deliver
cell-killing agents directly to cancer cells. ADCETRIS® (brentuximab
vedotin), the company’s lead product, in collaboration with Takeda
Pharmaceutical Company Limited, is the first in a new class of ADCs
approved globally in more than 60 countries for relapsed classical
Hodgkin lymphoma (HL) and relapsed systemic anaplastic large cell
lymphoma (sALCL). Seattle Genetics is also advancing vadastuximab
talirine (SGN-CD33A; 33A), an ADC that is expected to move into a phase
3 trial for acute myeloid leukemia in 2016. Headquartered in Bothell,
Washington, Seattle Genetics is also advancing a robust pipeline of
innovative therapies for blood-related cancers and solid tumors designed
to address significant unmet medical needs and improve treatment
outcomes for patients. The company has collaborations for its
proprietary ADC technology with a number of companies including AbbVie,
Astellas, Bayer, Genentech, GlaxoSmithKline and Pfizer. More information
can be found at www.seattlegenetics.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20160504005506/en/